2230. Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community-acquired Bacterial Pneumonia (CABP) Trial

BACKGROUND: DLX is a novel fluoroquinolone (FQ) antibiotic with Gram-positive/MRSA, Gram-negative and atypical activity. It offers IV and oral treatment with no QT restrictions. In a Phase 3 study in CABP patients, DLX was non-inferior to moxifloxacin (MOX) in the primary endpoint, early clinical re...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Open Forum Infect Dis
Main Authors: McCurdy, Sandra, Keedy, Kara, Lawrence, Laura, Sheets, Amanda, Quintas, Megan
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809893/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1908
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki